Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
BioLife Sciences (OTC: BLFE) recently witnessed its stock price increase by 33% on October 21, with a significant jump in the volume as well, reaching 2.5M shares traded. If the stock rebounded back up from its 5-day chart, it is still below the $0.03 mark occurring until October 11. Whether you invested early or after the drop, the current share price represents an excellent opportunity to get a positive return on investment.
BioLife Sciences (OTC: BLFE) provides disruptive technologies for the healthcare, beauty, and food & beverage sectors. The company develops, partners, and assists innovative companies with the commercialization of leading-edge technologies.
The company provides a broad range of services, including antimicrobial copper-infused textiles. Copper is a naturally-occurring metal that humanity has utilized since the early days. It has been used to produce weapons, tools, currency, and jewelry. Additionally, copper was long-touted in India for its health benefits long before scientists began understanding microbes and viruses. In ancient Egypt, copper was used to purifying water and prevent infections. This material is designed to inhibit virus & bacteria reproduction and cross-contamination before it starts. In other words, it will stop the spread before it starts. Copper-infused textiles were proven to prevent virus transmission from people who encounter the virus. The positive side is it fights against COVID-19 and other diseases, including MSRA and Ebola.
Additionally, the copper remains practical and durable even after repeated washes. BioLife also provides antimicrobial copper air filters. These air filters clean the air and release copper ions to protect against bacteria and germs circulating in enclosed rooms and buildings. It provides continuous protection for up to 30 days.
The company remained pretty silent for the last couple of weeks, but one important piece of news caught our eyes and did matter. BioLife negotiated with a Canadian firm, Work in Motion, to develop and commercialize custom-designed copper-infused bamboo gardening gloves for international distribution through Work in Motion’s extensive wholesale and distribution networks. Work In Motion is a leading products distributor and works alongside industry-leading manufacturers sourcing multidisciplinary products connecting international distribution chains alongside custom product development and private label services. BioLife Sciences will assume the sole responsibility for the development and commercialization of its copper-infused bamboo gardening gloves as a personal label design product around Work In Motion provided branding assets.
About finances, BioLife Sciences announced on July 15 that it qualified for the Reg A+ offering by the SEC. Resulting of this announcement, the company will be able to raise $20M at a public stock offering of $0.05 per share. By doing so, the company targets to become a fully reporting company and then apply for an uplisting to the OTCQB, known as the Venture Market.
“We are excited to have the opportunity to raise funds for the Company in order for us to reach our short-term goals, while laying the foundation for the Company to have continued success in the coming years.”
Nika Jaksic, COO of BioLife Sciences
This piece of news arrived on the market shortly before BioLife declared on August 17 that it launched a based product line. The company created its first line of cannabinoid consumer products and will be offering six distinct industrial hemp-based tincture formulations. These formulations were driven by the company’s recent acquisition of Health Box LLC in early 2022. BioLife wants to grow its hemp-based product line further once the tinctures have been released, with plans to expand to salves, syrups, coffees, teas, and lotions. This will grow this segment, along with CBD usage increasing in the US since 2018. Indeed, multiple studies confirmed cannabinoids might help with various aliments and conditions, including pain, stress, weight loss, anxiety, and depression. This industry is projected to keep expanding in 2022 to reach $22B by the end of the year.
Nika JAKŠIĆ (CEO) leads the company. In her past experiences, Nika JAKŠIĆ was the founder and former CEO of Health Box, which Biolife acquired in early 2022. She also spent years researching the relationship between aerobic fitness, nutritional therapy, meal planning, dietary guidance, and proper botanical supplement intake within the field of gerontology, with a focus on the loss of brain tissue in aging humans.
The market is anticipated to grow by USD 25.88 billion from 2020 to 2025. In addition, the market’s growth momentum will accelerate at a CAGR of 9.64% during the forecast period. The company intends to hire specialized online marketing firms to benefit market growth. BioLife wants to augment its presence on social media through social media campaigns (Twitter, Tik Tok, Facebook, Instagram, and Linkedin). The goal here is to generate leads from the public, small businesses, and large corporations about the benefits of BioLife products and their processes.
BioLife Sciences (OTC: BLFE) provides breakthrough technologies led by its Mfusion process. The company’s flagship project could result in a significant return on investment and significantly increase the company’s market cap. Moreover, its new partnership with Work In Motion should propel the company toward revenues. The extensive wholesale and distribution network is what BioLife needs, and the company continues to build its structure. More than ever, the company is undervalued and flies under the radar.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts